Veterans

Dr. Shai Efrati Honored With 2025 Ellis Island Medal of Honor

Hyperbaric oxygen therapy pioneer and Aviv Clinics medical advisor honored for research and service to veterans and patients with stroke,…

4 months ago

Trump Holds the Rescheduling Key: Will Marijuana Reform Follow the Patient’s Right to Try Path?

From ‘Right to Try' to Cannabis: Trump's Next Breakthrough Could Unlock FDA Trials."President Trump's marijuana decision must go beyond politics-patients…

4 months ago

Psyence Group Inc. Enters Into a Letter of Intent to Acquire Goldcoast Resource Corp.

TORONTO, ON / ACCESS Newswire / August 22, 2025 / Psyence Group Inc. (CSE:PSYG) ("Psyence" or the "Company"), announces that…

4 months ago

Vera Whole Health and Castlight Health Join Forces with Aligned Marketplace to Expand High-Quality Care Solutions

Strategic partnership expands access to advanced primary care for self-insured employers and unlocks integrated navigation nationwide SEATTLE and NEW YORK,…

4 months ago

Artera Achieves FedRAMP High “In Process” Status to Support Federal Agencies

Designation Is An Important Milestone In Artera's Journey To Equip Federal Agencies With Secure, AI-Powered Patient Communication Platform and Virtual…

4 months ago

Homecare Homebase Opens Nominations for 2025 Home Care Aide Scholarship Program

The annual scholarship initiative seeks to empower home care aides in their professional advancement, contributing to a highly motivated and…

4 months ago

Red Light Holland Applauds HHS Review of Psilocybin Rescheduling Petition, Expresses Optimism for Reversal of Schedule I Classification

Toronto, Ontario--(Newsfile Corp. - August 20, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…

4 months ago

genXtraits Inc. and Mendel Biotechnology, Inc. enter collaboration

ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- San Francisco Bay Area-based crop biotechnology firms genXtraits, Inc. (genXtraits) and Mendel…

4 months ago

First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS

Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to EnrollCAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE…

4 months ago